Latest news
Roivant Sciences shifts to commercial biopharma with $4.7B cash, eyeing FDA approval for brepocitinib by 2026 - PluangPluang · Sat, 08 Aug 2026 12:25:35 GMTRoivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist - simplywall.stsimplywall.st · Sat, 08 Aug 2026 06:38:12 GMTWall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 20:04:25 GMTsymbol__ Stock Quote Price and Forecast - CNNCNN · Fri, 07 Aug 2026 16:14:46 GMTRoivant Sciences Ltd. Q1 2026 Earnings Call Summary - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 12:30:00 GMTRoivant Sciences Q1 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 11:03:57 GMTRoivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:30 GMTTD Cowen raises Roivant Sciences stock price target to $50 on execution - Investing.comInvesting.com · Thu, 06 Aug 2026 20:06:00 GMT